Abstract
A recent study has concluded that the use of 123I-2β-carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl)nortropane single-photon emission computed tomography (123I-FP-CIT SPECT) is cost-effective or cost-saving in patients in whom the diagnosis of Parkinson disease versus essential tremor is uncertain. This conclusion is based on numerous assumptions, not all of which are likely to be universally applicable. The economic advantages associated with the use of 123I-FP-CIT SPECT will vary depending on the prevalence of Parkinson disease in the group of patients with uncertain diagnosis, the cost of usual clinical evaluation including other diagnostic tests, and the consequences of either delaying or inappropriately instituting dopaminergic therapy. The cost-effectiveness of radionuclide scanning is likely to increase in the future if a therapy is developed with a convincing impact on disease progression, the early institution of which confers a better outcome.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Benamer TS et al. (2000) Accurate differentiation of parkinsonism and essential tremor using visual assessment of 123I-FP-CIT SPECT imaging: the 123I-FP-CIT study group. Mov Disord 15: 503–510
Antonini A et al. (2008) Cost-effectiveness of 123I-FP-CIT SPECT in the differential diagnosis of essential tremor and Parkinson's disease in Italy. Mov Disord [10.1002/mds.22278]
Dodel RC et al. (2003) Dopamine transporter imaging and SPECT in diagnostic work-up of Parkinson's disease: a decision-analytic approach. Mov Disord 18 (Suppl 7): S52–S62
Jankovic J et al. (2000) The evolution of diagnosis in early Parkinson disease: Parkinson Study Group. Arch Neurol 57: 369–372
Olanow CW and Rascol O (2008) Early rasagiline treatment slows UPDRS decline in the ADAGIO delayed start study. Ann Neurol 64 (Suppl 12): S3
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author has acted as a consultant and received honoraria from Teva Pharmaceutical Industries.
Rights and permissions
About this article
Cite this article
Stoessl, A. Radionuclide scanning to diagnose Parkinson disease: is it cost-effective?. Nat Rev Neurol 5, 10–11 (2009). https://doi.org/10.1038/ncpneuro0986
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncpneuro0986
This article is cited by
-
Correlating Parkinson’s disease motor symptoms with three-dimensional [18F]FP-CIT PET
Japanese Journal of Radiology (2015)